查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
慢性阻塞性肺病市場:KOL的洞察
市場調查報告書
商品編碼
1715909

慢性阻塞性肺病市場:KOL的洞察

KOL Insight - Chronic Obstructive Pulmonary Disease
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入分析了慢性阻塞性肺病 (COPD) 治療的演變，重點關注固定劑量三聯療法的興起以及 Dupixent 和 Nucala 等生物製劑的引入。它提供了有關如何將這些治療方法納入嚴重 COPD 患者的治療方案以及最近的臨床試驗結果意味著什麼的見解。本文也討論了新型生物製劑對市場的影響，為醫藥專業人士提供了對 COPD 管理的當前趨勢和未來方向的深入分析。

主要問題解答

  • 哪些因素影響美國和歐洲對 COPD 三合一療法的接受度？
  • 三合一療法方案在不同患者族群中如何使用？
  • 第三階段 TRITON 試驗是否會獲得美國批准並在市場上取得成功？
  • Breztri/Trixeo 第 3 階段 KRONOS 資料的臨床影響為何？
  • Dupixent 在治療 COPD 的核准有何意義？它將佔據多少市場佔有率？
  • Nucala 和 Fasenra 在治療 COPD 方面的批准前景和競爭格局如何？

領導品牌

  • Breztri/Trixeo Aerosphere(Budesonide/Budesonide/gurikopiroreto)
  • torinbou(bekurometazon/Budesonide/gurikopironiumu)
  • toreji·eriputa(furuchikazonfuroeto/umekurijiniumu/Vilanterol)
  • deyupikusento(deyupirumabu)，nukara(meporizumabu)
  • Fasenra(benralizumab)，Ohtuvayre(ensifentrine)
  • itepekimabu
  • asutegorimabu
  • tozorakimabu
  • tanimirasuto
  • tezusupaia(tezeperumabu)

部分與會專家名單

    哈佛大學醫學教授、美國麻薩諸塞州波士頓布萊根婦女醫院主治醫師
  • 美國馬裡蘭州巴爾的摩市約翰霍普金斯醫院肺部與重症醫學系教授兼研究主任 美國賓州費城天普大學劉易斯卡茨醫學院胸腔外科系教授
  • 西班牙巴塞隆納 Vall d'Hebron 大學醫院肺科教授兼顧問 英國曼徹斯特大學、南曼徹斯特大學醫院 NHS 基金會感染、免疫和呼吸醫學教授
  • 法國巴黎大學呼吸醫學教授；科欽醫院 APHP 中心呼吸內科主任

研究方法

《治療趨勢》報告是透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，了解主要疾病領域的當前和未來治療前景而編寫的。 KOL 是根據嚴格的篩選標準精心挑選出來的，包括全球聲譽、臨床專業知識和其在治療領域的影響力。每次訪談都遵循精心設計的討論指南。這些指南是與 KOL 合作開發的，並經過行業專家的同行評審，以確保問題全面且與當前市場動態相關。透過在每份報告發布後12個月的持續市場監測，我們及時提供來自 KOL 的重大新聞事件、市場變化和市場發展的更新。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入、可行的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶了解新興趨勢並有效地解決複雜的挑戰。我們的報告以廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解為後盾，為您提供所需的準確性和可信度。獨家採訪和數據以及持續的市場監控使我們能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包含 KOL 洞察和定量醫生調查的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策並在快速變化的行業中保持競爭力。

簡介目錄

This report provides an in-depth analysis of the evolving landscape of chronic obstructive pulmonary disease (COPD) treatment, highlighting the increasing use of fixed-dose triple combination therapies and the introduction of biologics like Dupixent and Nucala. Gain insights into how these therapies are being integrated into treatment regimens for severe COPD patients and the implications of recent clinical trial results. The report also discusses the impact of new biologic therapies on the market, offering a detailed analysis of current trends and future directions in COPD management for pharmaceutical professionals.

Key Questions Answered:

  • What factors influence the uptake of triple therapies for COPD in the US and Europe?
  • How are triple therapies used across different patient populations?
  • Can Trimbow's Phase III TRITON study lead to US approval and market success?
  • What is the clinical impact of Breztri/Trixeo's Phase III KRONOS data?
  • How significant is Dupixent's approval for COPD, and what market share can it capture?
  • What are the approval prospects and competitive landscape for Nucala and Fasenra in COPD treatment?

Key Brands:

  • Breztri/Trixeo Aerosphere (budesonide/formoterol/glycopyrrolate)
  • Trimbow (beclometasone/formoterol/glycopyrronium)
  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
  • Dupixent (dupilumab), Nucala (mepolizumab)
  • Fasenra (benralizumab), Ohtuvayre (ensifentrine)
  • itepekimab
  • astegolimab
  • tozorakimab
  • tanimilast
  • Tezspire (tezepelumab)

Partial List of Participating Experts:

  • Professor of Medicine at Harvard Medical School and attending physician at Brigham and Women's Hospital, Boston, MA, US
  • Professor of Medicine and Director of Research, Division of Pulmonary and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, MD, US
  • Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, US
  • Professor and Consultant, Department of Pneumology, University Hospital Vall d'Hebron, Barcelona, Spain
  • Professor, Division of Infection, Immunity & Respiratory Medicine, University of Manchester, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK
  • Professor of Respiratory Medicine at Paris Cite University and Head of the Department of Respiratory Medicine, Cochin Hospital, APHP Centre, Paris, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.